M. Cucè

The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.

P. Tassone, P. Tagliaferri, V. Barbieri, 2018, Critical reviews in oncology/hematology.

Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients.

P. Tassone, P. Tagliaferri, C. Botta, 2017, Blood advances.

A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics

M. Cannataro, P. Tassone, P. Tagliaferri, 2022, Biomedicines.

Influence of the Fabrication Accuracy of Hot-Embossed PCL Scaffolds on Cell Growths

C. D. Critello, P. Tassone, P. Tagliaferri, 2020, Frontiers in Bioengineering and Biotechnology.

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells

N. Munshi, C. Mignogna, P. Tassone, 2017, Leukemia.

A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival

P. Tagliaferri, C. Botta, M. Rossi, 2016, Blood Cancer Journal.

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma

P. Tassone, P. Tagliaferri, V. Barbieri, 2019, Journal of Hematology & Oncology.

Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment.

P. Tassone, P. Tagliaferri, D. Caracciolo, 2017, Current cancer drug targets.

A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival

P. Tassone, P. Tagliaferri, C. Botta, 2016, Blood Cancer Journal.